Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (21): 3847-3850.doi: 10.3969/j.issn.1673-8225.2011.21.011

Previous Articles     Next Articles

Targeting effect of hyaluronic acid coupled chitosan nanoparticles on non-small cell lung cancer

Liang Heng-lun1, Li Jing2, Tong Jian1, Zhang Fu-wei1, Ruan Bao-qin1   

  1. 1Department of Cardiothoracic Surgery, 2Oncology Center, Zhujiang Hospital, Southern Medical University, Guangzhou  510282, Guangdong Province, China
  • Received:2011-02-21 Revised:2011-04-24 Online:2011-05-21 Published:2011-05-21
  • Contact: Tong Jian, Professor, Master’s supervisor, Department of Cardiothoracic Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, Guangdong Province, China Tongjian@hotmail.com
  • About author:Liang Heng-lun★, Studying for master’s degree, Physician, Department of Cardiothoracic Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, Guangdong Province, China liangalun2008@yahoo.com.cn

PDF

833

Abstract:

BACKGROUND: CD44 has been found to be over-expressed in non-small cell lung cancer (NSCLC). Hyaluronic acid (HA) has a high affinity state with CD44 and has the potential as a targeted delivery vehicle for chemotherapy agents.
OBJECTIVE: To evaluate the targeting effect of HA coupled chitosan nanoparticles (HACTNPs) on NSCLC.
METHODS: HACTNPs bearing Docetaxel (DTX-HACTNPs) were prepared by ionotropic gelation. The nanoparticles were characterized for their shape by transmission/scanning electron microscopy. The particle size distribution was assessed by laser scattering. The biocompatibility of FITC-labeled nanoparticle formulations was evaluated for in vitro cytotoxicity by MTT assay using CD44+A549 cell lines.
RESULTS AND CONCLUSION: The DTX-HACTNPs appeared to be spherical in shape and the mean size was found to be around (228.0±2.6) nm with low polydispersity index. The cytotoxicity of DTX-HACTNPs was higher than that of DTX-CTNPs, but lower than that of conventional DTX for injection. And their IC50 were (15.06±0.94), (25.73±3.37), (5.35±0.61) mg/L, respectively (F=73.871, P=0.000). The results indicate that HACTNPs are anticipated to be promising alternate carriers for targeting of CD44+ tumor cells.

CLC Number: